Home | | Pharmaceutical Biotechnology: Fundamentals and Applications | Interleukins: Nomenclature and Functions

Chapter: Pharmaceutical Biotechnology: Fundamentals and Applications : Interferons and Interleukins

Interleukins: Nomenclature and Functions

ILs are primarily a collection of immune cell growth, differentiation and maturation factors. Collectively they orchestrate a precise and efficient immune response to toxins and pathogens, including cancer cells, recognized as foreign.


ILs are primarily a collection of immune cell growth, differentiation and maturation factors. Collectively they orchestrate a precise and efficient immune response to toxins and pathogens, including cancer cells, recognized as foreign. As is the case for IFNs, ILs bind to related specific cell surface receptors which activate similar intracellular signaling cascades (Lutfalla et al., 2003; Pestka et al., 2004b; Huising et al., 2006). Many ILs, primarily those with proin-flammatory function, are intrinsically toxic either directly or indirectly, i.e., through induction of toxic gene products. Therefore the human body has an elaborate system of checks and balances that, under (patho)-physiological conditions, regulates the mag-nitude and duration of an immune response. Under biological conditions, ILs usually have a short circulation time, and their production is regulated by positive and negative feedback loops. Furthermore their effect is mostly localized, and in some cases soluble receptors (sR) or neutralizing antibodies limit their dissemination. Specific receptor antagonists can also control their activity.

Table 2 lists the ILs for which the protein and gene structure have been characterized. Their names and symbols have been approved by the HGNC.

Under physiological conditions, the relative concentrations of agonistic and antagonistic ILs establish a delicate balance in driving pro- and anti-inflammatory processes. This balance can be dis-turbed by various pathogenic agents or mechanisms:


·     Infectious agents or toxins


·     Allergens


·     Malignant tumors


·     Genetic variants

These pathogenic agents or mechanisms result in a self-limited or protracted disequilibrium. Symptoms of disease can be the consequence of an adequate immune response at the end of which the steady-state is reestablished. A brisk inflamma-tory response is the sign of a healthy immune reaction. In some instances an inadequate response can manifest itself as relapsing remitting progres-sive disease, e.g. rheumatoid arthritis, asthma, chronic inflammatory bowel disease, multiple sclerosis, chronic hepatitis, or chronic insulitis leading to diabetes mellitus. All have in common that they need a genetic predisposition and an environmental trigger factor to become active, and are at best only partially understood. In many cases these diseases are caused by either insufficient production or overproduction of key ILs. Thus, in principle, once the diagnosis is made these ILs can be therapeutically supplemented or suppressed to restore proper balance (Ryff, 1996).

Our current knowledge of the ILs listed in Table 2 is briefly summarized below and each reference selected expands on the subject. Readers interested in the current knowledge about the protein, DNA, RNA, gene, chromosome location, etc. for individual IFNs or ILs is referred to the following databases:


1.     www.genatlas.org (with a links to other data-bases), or

2.     http://au.expasy.org/sprot/, or


3.     www.rcsb.org/pdb/ for the 3D models of indivi-dual IFNs or ILs.


Interleukin-1 Family


IL-1 (Towne et al., 2004) is generally used to describe IL-1a and IL-1b both of which have the same biological effects and play a primordial role in the innate and adaptive immune response. Although the prototypical proinflammatory cytokine, it also plays a key role in hematopoiesis, appetite control, and bone metabolism.


IL-1 is released as part of the acute phase reaction of hepatocytes. The primary producers of IL-1 are macrophages, B-cells and neutrophils. IL-1a and IL-1b are synthesized as propeptides of approxi-mately 30 kDa, and are then cleaved to produce products of 159 and 153 amino acids. Differences in glycosylation are responsible for the wide variation of reported molecular weights.


There are several other members of the IL-1 family. One is a naturally occurring inhibitor of IL-1. This IL-1 receptor antagonist (IL-1Ra) has limited sequence similarity to either IL-1a or IL-1b, but does have the ability to bind to the IL-1 receptors. Lacking IL-1 activity, it acts as a useful blocker of the receptor. A recombinant IL-1Ra has been investigated for its potential use in sepsis; however, the clinical trials were inconclusive. Recombinant IL-1Ra has however been used successfully in treatment of rheumatoid arthritis and is marketed under the name of Kineret (see section “Therapeutic Use of Recombinant Interleukins”).

Interleukin 2


IL-2 (Nelson, 2004) is a typical four a helix cytokine originally described as T-cell GF (TCGF). Synthesized and secreted primarily by T-cells, IL-2 can stimulate the growth, differentiation and activation of T-cells, B-cells, and NK-cells. The new understanding of IL-2 biology is that its major physiological effect is to promote self-tolerance by suppressing T-cell response in vivo. Three chains comprise the cellular high affinity IL-2 receptor—the α, β and γ chains. IL-15 is closely related to IL-2 with which it shares the β and γ signaling receptor subunits. A soluble form of the IL-2R capable of binding IL-2, a truncated version of the a chain without cytoplasmic tail, has been found in human serum (sR). High levels of IL-2sR have been found in patients with a wide variety of disorders, including chronic hepatitis C, HIV infection, cancer, solid organ transplant rejection, and arthritis. Soluble IL-2R can bind released IL-2 prior to its binding to cells to preventoverflow or over-stimulation. Several other cytokine and adhesion molecule receptors also have circulat-ing forms. This is one manner in which the immunological cascade maintains its checks and balances.

Interleukin 3

generation of hematopoietic progenitors of every lineage. Administration of IL-3 produces an increase in erythrocytes, neutrophils, eosinophils, monocytes and platelets. IL-3, however, is not involved inconstitutive hematopoiesis but rather in inductive hematopoiesis upon exposure to immunological stress. IL-3 can act synergistically or additively with other hematopoietic GFs.

Interleukin 4


IL-4 (Steinke and Borish, 2001) is produced by Th2 cells and by mast cells, basophils, and eosinophils. It stimulates B-cell proliferation and activation, induces class switch to IgE and IgG1 expression from B-cells, as well as class II Major Histocompatibility Complex (MHC) expression. In addition it induces the differentiation of eosinophils and activity of cytotoxic T-cells. IL-4 regulates the differentiation of helper T-cells to the Th2 type. These T-cells produce the cytokines IL-4, IL-5, IL-9, and IL-13, which can all participate in the allergic response. IL-4 regulates the production of IgE by B-lymphocytes. It also has the ability to stimulate CK production and mucus hypersecretion by epithelial cells. IL-4 can elicit many responses, some of which are associated with allergy and asthma.

Interleukin 5

IL-5 (Greenfeder et al., 2001) acts as a homodimer originally known as T-cell replacement factor (TRF), eosinophil differentiation factor (EDF) and B-cell GF (BCGFII). It is produced by a number of cell types. It acts on the eosinophilic lineage, stimulating eosino-phil expansion and chemotaxis and also has activity on basophils. In humans IL-5 is a very selective cytokine as only eosinophils and basophils express IL-5 receptors.

Interleukin 6


IL-6 (Heinrich et al., 1990) is produced by lymphoid and nonlymphoid cells. By stimulating hepatocytes to produce “acute phase proteins” it plays a central role in the “acute phase reaction.” It is also responsible for the reactive thrombocytosis seen in acute inflamma-tory processes by stimulating thrombopoietin (TPO) (Kaushansky, 2005). IL-6 was formerly known as IFNβ2 for its weak antiviral activity. IL-6 is also associated with insulin resistance in obese individuals (Esposito et al., 2003).

Interleukin 7


IL-7 (Fry and Mackall, 2002) is a glycosylated essen-tially tissue-derived cytokine. Its primary sources are stromal and epithelial cells in various locations includ-ing intestinal epithelium, liver and to a lesser degree dendritic cells. IL-7 acts primarily on pre-B-cells to stimulate their differentiation. It can also stimulate the development of human T-cells. IL-7 is classified as a type I short chain cytokine of the hematopoietin family which also includes IL-2, IL-3, IL-4, IL-5, GM-CSF, IL-9, IL-13, IL-15, M-CSF and stem cell factor (SCF).

Interleukin 8


IL-8 (Remick, 2005) is a 6 to 8 kDa CXC CK, a potent chemoattractant for neutrophils. It affects the proin-flammatory effector side, including the stimulation of neutrophil degranulation and the enhancement of neutrophil adherence to endothelial cells. It is produced by monocytes, macrophages, fibroblasts, keratinocytes and endothelial cells. Elevated levels of IL-8 have been found in psoriatic arthritis, synovial fluid and syno-vium. IL-8 has been implicated in angiogenesis.

Interleukin 9


IL-9 (Zhou et al., 2001) is a Th2 cytokine originally characterized as a factor produced by activated T-cells and able to support the long-term growth of some T-helper clones. IL-9 activities extend to various cell types including mast cells, B-lymphocytes, hemo-poietic progenitors, eosinophils, lung epithelial cells,neuronal precursors and T-lymphocytes. Increased IL-9 production has been implicated in major pathologies such as asthma supported by its effects on IgE production, mucus production, mast cell differentia-tion, eosinophil activation and bronchial hyperre-sponsiveness. IL-9 stimulates the growth of murine thymic lymphomas and an autocrine loop has been suggested in Hodgkin lymphoma. Finally, IL-9 is required for an efficient immune response against intestinal parasites. IL-9 exerts its effects through a receptor that belongs to the hemopoietic receptor superfamily and consists of two chains, also involved in IL-2, IL-4, IL-7, and IL-15 signaling.

Interleukin 10


Macrophages are the major source of IL-10 (Asadullah, 2004), which Th2 cell subsets, monocytes and several other cells can also synthesize. It is a homodimer, whereby each monomer consists of 160 amino acids with a MW of 18.5 kDa. IL-10 is a major endogenous anti-inflammatory mediator which acts by profoundly inhibiting the synthesis of proinflam-matory molecules. A number of molecules produced under stress conditions including reactive oxygen species stimulate IL-10 synthesis. Recombinant hu-man IL-10 has been tested in clinical trials in rheumatoid arthritis, inflammatory bowel disease, psoriasis, organ transplantation, and chronic hepatitis C. The results are mixed, however they give new insight into the immunobiology of IL-10 and suggest that the IL-10/IL-10R system may become a new therapeutic target. Several novel IL-10 related class 2 cytokines have recently been discovered (Pestka et al., 2004b). These include IL-19, -20, -22, -24, -26, -28A, -28B and -29. The receptor complexes for IL-22, IL-26, IL-28A, IL-28B and IL-29 are distinct from that used by IL-10; however, all of these cytokines use a common second chain, IL-10 receptor-2 (IL-10R2; CRF2-4), to assemble their active receptor complexes (Donnelly et al. 2004; Pestka et al., 2004b).



Interleukin 11


IL-11 (Du and Williams, 1997) initially described as hematopoietic factor with thrombopoietic activity has subsequently been shown to be expressed and active in many other tissues including brain, spinal cord neurons, gut, and testes. IL-11 acts synergistically with other cytokines such as IL-3, -4, -7, -12, -13, SCF and GM-CSF to stimulate various stages and lineages of hematopoiesis and in particular with IL-3 and TPO, also termed megakaryocyte growth and development factor (MGDF), to stimulate various stages of mega-karyocytopoiesis and thrombopoiesis. Treatment with IL-11 results in production, differentiation, andmaturation of megakaryocytes. IL-11 also has a direct effect on erythroid progenitors and also modulates the differentiation and maturation of myeloid progenitor cells. Alveolar and bronchial epithelial cells produce IL-11, which is upregulated by inflammatory cyto-kines and respiratory syncitial virus (RSV) suggesting that it plays a role in pulmonary inflammation. IL-11 also is an important regulator of bone metabolism.

Interleukin 12


IL-12 (Adorini, 1999) is a 75-kDa heterodimeric proinflammatory cytokine composed of two cova-lently linked glycosylated chains: p35 and p40. It is produced predominantly by activated monocytes and dendritic cells, enhances proliferation and cytolytic activity of NK- and T-cells, and stimulates their IFNγ production, guiding them toward a Th1 response while it inhibits Th2 cells. Because of these properties, the regulation of IL-12 production and its alteration in certain disease states have major relevance for the modulation of immune and allergic responses, and recombinant IL-12 has several potential therapeutic uses in infectious diseases, allergy, and cancer.

Interleukin 13

Human IL-13 (Wills-Karp, 2004) is a 17 kDa glycopro-tein cloned from activated T-cells. IL-13 was first recognized for its effects on B cells and monocytes, where it upregulated class II expression, promoted IgE class switching and inhibited inflammatory cytokine production. IL-13 possesses several unique effector functions that distinguish it from IL-4. Resistance to most gastrointestinal nematodes is mediated by type-2 cytokine responses, in which IL-13 plays a dominant role. By regulating cell-mediated immunity, IL-13 modulates resistance to intracellular organisms. In the lung, IL-13 is the central mediator of allergic asthma, where it regulates eosinophilic inflammation, mucus secretion, and airway hyperresponsiveness. IL-13 can also inhibit tumor immunosurveillance. Thus, inhibi-tors of IL-13 might be effective as cancer immunother-apeutics by boosting type-1-associated antitumor defenses. Investigations into the mechanisms that regulate IL-13 production and/or function have shown that IL-4, IL-9, IL-10, IL-12, IL-18, IL-25, IFNγ, TGF-b, TNF-a, and the IL-4/IL-13 receptor complex play important roles in this process.

Interleukin 15


IL-15 (Fehniger and Caligiuri, 2001) shares the IL-2bg receptor complex components IL-2Rb (CD122) and IL-2Rg (CD132), however specificity is conferred by a unique a-chain (IL-15Ra) completing the IL-15Rabg heterotrimeric high affinity receptor complex. IL-15exhibits characteristics of IL-2 such as stimulation of T-cells, but the third receptor chain (IL-15Ra) distin-guishes its activities and specificities. In addition, IL-15 and its receptor have a much wider tissue distribution than IL-2 and its receptor.

Interleukin 16


IL-16 (Cruikshank et al., 1998) is a proinflammatory cytokine, which induces chemotaxis of CD4þ T-cells, monocytes and eosinophils. It has been shown to play a role in asthma (El Bassam et al., 2005), Crohn’s Disease (CD) (Middel et al., 2001) and systemic lupus erythematosus (SLE) (Lee et al., 1998). IL-16 also inhibits human (HIV) and simian (SIV) immunodefi-ciency virus. A neuronal form of IL-16 detected in neurons of the cerebellum and hippocampus has been described (Kurschner and Yuzaki, 1999).

Interleukin 17 Family


IL-17 (Kolls and Linde´, 2004) a homodimeric glycoprotein more recently renamed IL-17A is the prototypic IL-17 family member. It is produced by activated T-cells, but its receptor is expressed in every tissue examined. Subsequently, five additional family members IL-17B to IL-17F have been discovered. The importance of this family of cytokines and their receptors expressed in disparate tissues goes beyond the modulation of T-cell-mediated inflammatory response and importance in effective host defense against gram-negative bacteria. IL-17 cytokines have also a role in the homeostasis of tissues and the progression of diseases such as arthritis (Gaffen, 2004; Lubberts et al., 2005), and cancer, e.g. prostate cancer (Moseley et al., 2003).

Interleukin 18


IL-18 (Liu et al., 2000) shares unique structural features with the IL-1 family, but it does not have the usual four-helix structure rather an all β-pleated sheet structure. It is produced by activated macro-phages such as Kupffer cells of the liver and other resident macrophages from which the mature protein is released. IL-18 is an early inducer of the Th1 response, costimulating, with IL-12, the production of IFNγ, TNF-a, GM-CSF and IL-2. IL-18 is associated with the Metabolic Syndrome and coronary vascular disease (Hung et al., 2005).

Interleukin 19


IL-19 (Gallagher et al., 2000; Chang et al., 2003) is a newly discovered member of the IL-10 family whose function is presently undefined. The induction of IL-19 in human monocytes is downregulated by IFNγ

and upregulated by IL-4. IL-19 plays a role in the Th1/Th2 system. IL-19 is able to influence the maturation of human T-cells. CD4þ T-cells resulting from staphylococcal enterotoxin B (SEB) stimulation in the presence of IL-19 contained a higher proportion of IL-4 producing cells than those developing in the absence of IL-19. This observation was complemented by the observation that fewer IFNγ cells accrued in the presence of IL-19, thereby suggesting that IL-19 altered the balance of Th1/Th2 cells in favor of Th2 cells. Furthermore, in cultures of whole peripheral blood mononuclear cells (PBMC) IL-19 upregulated IL-4 and downregulated IFNγ in a dose-dependent manner.

Interleukin 20


IL-20 (Blumberg et al., 2001) was originally identified from a keratinocyte library, mRNA isolated from skin and trachea. Analysis of the entire coding sequence yielded a 176 amino acid sequence classified as a helical cytokine member of the IL-10 family. IL-1b, TGF-a and epidermal GF (EGF), factors known to be involved with proliferative and proinflammatory signals in the skin, enhance the response to IL-20. Two orphan class 2 cytokine receptors, both expressed in skin, have been discovered and labeled IL-20Ra and IL-20Rb; both are required for IL-20 binding and mRNA for both are markedly upregulated in psoriatic compared to normal skin.

Interleukin 21


IL-21 (Sivakumar et al., 2004), a four-helix cytokine, is a new member of the IL-2 family of cytokines that utilize the common g-chain receptor subunit for signal transduction. The heterodimeric IL-21R has a IL-21-specific subunit besides the g-chain. IL-21 expression is restricted primarily to activated CD4þ T-cells. IL-21 expression seems transient and stage specific during T-cell differentiation. It is required for normal humor-al immunity and regulates antibody production in cooperation with IL-4. IL-21 also regulates cell-mediated immunity by inducing IFNγ, TNF-a, synth-esis of perforin and granzyme B leading to cytolytic activity. It can cooperate with other cytokines to generate potent killer T-cells and thus has antitumor activity. Lastly it also has inhibitory activity by inducing IL-10. Thus, altogether, it is responsible for the coordination of the initiation and cessation of an immune response.

Interleukin 22


IL-22 (Kotenko et al., 2001a,b; Boniface et al., 2005) belongs to a family of cytokines structurally related to IL-10, including IL-19, IL-20, IL-24, and IL-26. In contrast to IL-10, it has proinflammatory activities: it upregulates the production of acute phase proteinsand pancreatitis-associated protein 1. The IL-22 receptor is composed of an IL-22-binding chain, IL-22R1 and the IL-10R2 subunit, which is shared with the IL-10R. IL-22 is produced by activated human Th cells and mast cells. A soluble IL-22-binding protein, IL22RBP, encoded by a distinct gene, has been identified. This sR, which has 34% amino acid identity to the extracellular domain of the IL-22R1, binds IL-22 and antagonizes its functional activities. The skin is also a target for IL-22; high IL-22 expression has been detected in the skin of patients with T-cell-mediated dermatoses. Normal human epidermal keratinocytes express a functional receptor for IL-22 but not for IL-10. IL-22 plays a role in skin inflammatory processes and wound healing.

Interleukin 23


IL-23 (Aggarwal et al., 2003) is a heterodimeric cytokine comprising the IL-12 p40 subunit and an IL-23-specific p19 subunit. It is produced by activated dendritic cells and acts on memory CD4þ T-cells. IL-23 induces IL-17 and thus plays an early role in defense against gram-negative infection. It is also pivotal for establishing and maintaining organ-spe-cific inflammatory autoimmune disease. IL-23 and IL-27 both have potent antitumor activity even against poorly immunogenic tumors using different effector mechanisms.

Interleukin 24


IL-24 (Jiang et al., 1996; Wang and Liang, 2005) is a novel member of the IL-10 family secreted by activated PBMC and the ligand for two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. The latter is also a receptor chain for IL-20. Under physiological conditions, the major sources of IL-24 are activated monocytes and Th2 cells, whereas the major IL-24 target tissues, based on the receptor expression pattern, are nonhematopoietic in origin, and include skin, lung and reproductive tissues. Structurally and functionally, IL-24 is highly con-served across species. It has shown antiangiogenic activity and its gene is a tumor suppressor gene (Ishikawa et al., 2005).


 Interleukin 25


IL-25 (Fort et al., 2001), although structurally related to IL-17, is a protein of approximately 17 kDa. It is produced by Th2-polarized T-cells, and its biological effects differ markedly from those of the previously described IL-17 family members. IL-25 induces IL-4, -5 and -13 and causes histological changes in the lungs and GI tract, including eosinophilic and mononuclear infiltrates, increased mucus production, and epithelial cell hyperplasia and hypertrophy. IL-12 appears to be a key cytokine for the development of Th2-associatedpathologies such as asthma and other allergic reac-tions, as well as antiparasitic response.

 Interleukin 26


IL-26 (Fickenscher and Pirzer, 2004; Ho¨r, 2004) is a polypeptide of 177 amino acids and is part of the IL-10 family. IL-26 is produced in activated Th1 memory cells, to some extent in NK cells, but neither in Th2 or regulatory T-cells, nor in monocytes or B-cells. IL-26 is normally expressed by various sorts of T-cells at low levels, and specifically overexpressed by T-cells after Herpesvirus saimiri (HVS) transformation. It binds to aheterodimeric receptor postulated to be comprised of the IL-20R1 and IL-10R2 chains. Targeting epithelial cells, the T-cell lymphokine IL-26 is likely to play a role in local mechanisms of mucosal and cutaneous immunity.

 Interleukin 27


IL-27 (Villarino and Hunter, 2004) is a novel hetero-dimeric cytokine of the IL-12 family that consists of EBI3, an IL-12p40-related protein, and p28, a newly discovered IL-12p35-related polypeptide. It is pro-duced by antigen-presenting cells and specifically acts on naı¨ve T-cells. IL-27 synergizes with IL-12 to produce IFNγ and does not support Th2 cytokine production by activated T-cells. Recent evidence however suggests that this receptor/ligand pair is also required to suppress a variety of immune cell effector processes, including proliferation and cytokine production. There is some evidence for the protective role of IL-27 from inflammatory autoimmune diseases and it has been shown to have antitumor effects in animal models (Hisada et al., 2004).

 Interleukin 28 and Interleukin 29


Recently, the human genomic sequence for a family of three cytokines, designated IL-28A, IL-28B and IL-29 (Sheppard, 2002), that are distantly related to type I IFNs and the IL-10 family has been described (Pestka et al., 2004a,b). Like type I IFNs, IL-28 and IL-29 are induced by viral infection and have antiviral activity. However, IL-28 and IL-29 interact with a heterodimeric class 2 cytokine receptor that consists of the IL-10 receptor 2 (IL-10R2) and an orphan class 2 receptor chain, designated IL-28R1. This newly described cytokine family may serve as an alternative to type I IFNs in providing immunity to viral infection.

 Interleukin 31


IL-31 (Bilsborough et al., 2006) is a newly discovered four-helix bundle cytokine preferentially expressed by activated T-cells with a Th2 bias. Together with IL-4 and IL-13, IL-31 has been implicated in the pathogen-esis of atopic dermatitis because they are produced by a subset of T-cells that home to the skin. IL-31 signalsthrough a heterodimeric receptor constitutively ex-pressed by epithelial cells including keratinocytes. IL-31 stimulated keratinocytes induce a whole array of inflammatory CKs which also facilitate the recruit-ment of lymphocytes, monocytes and polymorpho-nuclear cells to the epidermis.



 Interleukin 32


IL-32 (Kim et al., 2005) is a recently characterized polypeptide which was described several years ago as natural killer cell transcript 4 (NK4) of activated T-cells and NK-cells and belongs to the proinflamma-tory cytokines. It induces TNF-a and MIP-2, a CK, in different cells via the signal pathway of proinflamma-tory cytokines. To date it has been detected in higher concentration in some of the patients with sepsis compared to healthy individuals.


 Interleukin 33


IL-33 (Schmitz et al., 2005), unlike other members of the IL-1 ligand family, which are all proinflammatory, has a major role in the development of a Th2 type immune response by inducing IL-5 and IL-13. Human smooth muscle cells as well as epithelial cells forming bronchus and small airways show constitutive expression of IL-33 mRNA; in lung or dermal fibroblasts and keratinocytes IL-33 mRNA is induced after activation with TNF-a and IL-1b. Activated dendritic cells and macrophages are the only hematopoietic cells showing low quantities of IL-33 mRNA. In addition, IL-33 and IL-18 are the only known IL-1 family member genes not located on chromosome 2.


Study Material, Lecturing Notes, Assignment, Reference, Wiki description explanation, brief detail
Pharmaceutical Biotechnology: Fundamentals and Applications : Interferons and Interleukins : Interleukins: Nomenclature and Functions |

Privacy Policy, Terms and Conditions, DMCA Policy and Compliant

Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.